InSilico Medicine Cayman TopCo stock

3696 · HKEX · HKD

Compare InSilico Medicine Cayman TopCo
$30.60Change from previous close: −8.55%Absolute change: −$2.86

Close · November 20, 2026

Price history

−18.57% over the period

Full history: from $37.58 (January 2, 2026) to $30.60 (November 20, 2026), −18.57%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$30.60
October 30, 2026$36.00
September 25, 2026$55.65
August 28, 2026$46.30
July 31, 2026$45.70
June 26, 2026$38.22
May 29, 2026$41.58
April 30, 2026$63.05
March 27, 2026$57.20
February 27, 2026$61.95
January 30, 2026$62.90
January 2, 2026$37.58

At a glance

  • The company

    Applies artificial intelligence to drug discovery and development using its proprietary Pharma.AI platform

  • Latest results

    Quarter to June 30, 2026 · EPS $0.06

TickerLandia's take on InSilico Medicine Cayman TopCo

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$29.98
52-wk high$80.90

−62.18% from the 52-week high

Analysts · 12 analysts

Average target$76.70+150.65% vs. price

Buy 12 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: InSilico Medicine Cayman TopCo

Compared with similar companies: very high risk and very weak momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

InSilico Medicine Cayman TopCo is cheaper than similar companies

InSilico Medicine Cayman TopCo's Forward P/E: 19.9, −45% against the median of a group of 9 similar companies (36.1).

Compared with 9 similar companies

InSilico Medicine Cayman TopCo's metrics compared with similar companies
MetricInSilico Medicine Cayman TopCoPosition in the groupBand
Forward P/E19.9Low
Operating margin-6.9%Middle
ROE443.1%High
Debt/equity0.04Low
Price/book4.64Middle

Grey band: the middle half of the group; tick: the median; dot: InSilico Medicine Cayman TopCo. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$106.3M

Latest quarter · Q2 2026

Net income

$35.54M

Latest quarter · Q2 2026

Quarterly net margin

33.4%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$20.31B
EPS
-$34.26
Volume
6.15M
Daily trading
€42.69M
Dividend yield
0.00%

How InSilico Medicine Cayman TopCo is changing

All results
  • Revenue grew 23.1% a year on average over the last 3 years

  • Operating margin rose from −265.8% to −106.7%

  • Shares outstanding up 17.4% in 3 years

Returns

InSilico Medicine Cayman TopCo returns

PeriodInSilico Medicine Cayman TopCoHang Seng$1,000 becomes
1 month−22.41%−6.10%$776
6 months−36.46%−12.63%$635
Year to date−17.79%−12.56%$822

Over the last 6 months it has done better than 6% of the stocks in the Healthcare sector.

Price only, without dividends.

The chart in detail

InSilico Medicine Cayman TopCo: technical analysis

InSilico Medicine Cayman TopCo is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 60.2% below its all-time closing high ($76.85, February 16, 2026).

Trend
Downward
RSI (14 sessions)
29
Below 30: a strong fall in a short time
vs 200-session average
−39.20%

Active signals

  • Close below the low of the previous 55 sessions.

  • RSI below 30: the stock has fallen a lot in a short time.

Support and resistance

Price areas where InSilico Medicine Cayman TopCo has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$41.18+34.58%2 touches, last on November 12, 2026
  2. Resistance$39.15+27.93%3 touches, last on August 19, 2026
  3. Resistance$34.04+11.24%2 touches, last on October 23, 2026
  4. Last price$30.60
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.64
Volatility (60 sessions, annualised)
76.5%
Largest fall in the last year
−60.18%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

InSilico Medicine Cayman TopCo and its competitors

Employing 333 people, InSilico Medicine Cayman TopCo applies artificial intelligence to drug discovery and development through its proprietary Pharma.AI platform, which offers target identification, small molecule generation and clinical outcome prediction. Its pipeline covers fibrosis, oncology, immunology, metabolic and anti-pain programs, and its work runs through research and development collaborations with partners including Takeda and Servier, as well as a strategic agreement with Suzhou Ribo Life Science on oligonucleotide therapeutics.

Headquarters
Hong Kong, Hong Kong
Employees
333
Founded
2014
InSilico Medicine Cayman TopCo and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
InSilico Medicine Cayman TopCo3696$2.59B-6.9%—−36.46%
Telix PharmaceuticalsTLX$2.92B6.2%92.3−7.71%
Neuren PharmaceuticalsNEU$1.83B19.9%144.0+68.84%
MesoblastMSB$1.48B-42.6%—−14.82%
3SBio1530$4.56B60.3%3.90−34.08%
Metis TechBio7666$1.11B-131.2%—−63.08%

Same industry or related industries, similar size. Compare InSilico Medicine Cayman TopCo with its competitors · Full profile